Fibrodysplasia ossificans progressiva

5 trials 2 recruiting MedDRA PT
5 Registered trials
2 Recruiting
4 Unique sponsors
5 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Monoclonal antibody 1 substance
Kinase inhibitor 1 substance
Phase III: 1 Phase II: 3 Phase IV: 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

1 trial
  • Regeneron Pharmaceuticals Inc. Commercial
    GARETOSMAB
    2023-508350-26-00 6 countries 2023 n=24 Orphan
    Ended

Phase II

3 trials
  • Clementia Pharmaceuticals Inc. An Ipsen Company Commercial
    (R)‑TETRAHYDROFURAN‑3‑YL 4‑(6‑(5‑(4‑ETHOXY‑1‑ISOPROPYLPIPERIDIN‑4‑YL)PYRIDIN-2-YL)PYRROLO[1,2-B]PYRIDAZIN-4-YL)PIPERAZINE-1-CARBOXYLATE SESQUISUCCINATE
    2024-511469-13-00 8 countries 2021 n=34 Orphan
    Ended
  • Incyte Corp. Commercial
    INCB000928
    2023-504129-38-00 6 countries 2022 n=18
    Recruiting
  • Amsterdam UMC Stichting Academic
    SARACATINIB
    2024-515186-33-00 2 countries 2020 n=18
    Ended

Phase IV

1 trial
  • Amsterdam UMC Stichting Academic
    BRETOVAMERAN
    2024-518686-10-00 1 country 2025 n=10
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amsterdam UMC Stichting Academic 2 Phase II, Phase IV 1
Clementia Pharmaceuticals Inc. An Ipsen Company Commercial 1 Phase II 0
Incyte Corp. Commercial 1 Phase II 1
Regeneron Pharmaceuticals Inc. Commercial 1 Phase III 0
New trials by year
2020
1
2021
1
2022
1
2023
1
2025
1
← All indication landscapes